05:35am Thursday 23 November 2017

High cholesterol during young adulthood raises heart disease risk

Study Highlights:

  • How long you have elevated cholesterol – even if only mildly elevated –affects your risk of heart attack.
  • Every decade you have elevated cholesterol between the ages of 35 and 55 may increase your future risk of heart disease by 39 percent.

DALLAS—new research in the American Heart Association’s journal Circulation shows that long-term exposure to elevated cholesterol substantially increases lifetime risk for heart disease. For every ten years you have even mildly elevated cholesterol between the ages of 35 and 55, your risk of heart disease may be increased by nearly 40 percent.

“Our findings suggest that  they [adults with longstanding mild to moderately [taken from the manuscript] elevated cholesterol levels] may benefit from more aggressive prevention strategies earlier,” said lead study author Ann Marie Navar-Boggan, M.D., Ph.D, and cardiology fellow at the Duke Clinical Research Institute in Durham, N.C.

Researchers studied data from the Framingham Heart Study, which began in 1948 and remains one of the largest ongoing research projects focused on heart health. The study evaluated 1,478 adults who were free of cardiovascular disease at the age of 55 years, and  calculated the length of time each participant had experienced high cholesterol by that age. These adults were then followed for up to 20 years to see how duration of exposure to high cholesterol affected their risk of heart disease. At age 55, 389 had experienced one to 10 years of elevated cholesterol, 577 had 11 to 20 years of high cholesterol and 512 participants did not have high cholesterol.

Results demonstrated a dose-response relationship between duration of cholesterol exposure by age 55 and future risk of heart disease:

  • Participants with 11 to 20 years of high cholesterol had a 16.5 percent overall risk of heart disease.

  • Those with one to 10 years of cholesterol exposure had 8.1 percent risk.

  • Those who did not have high cholesterol at the start of the study had only a 4.4 percent risk for heart disease.

  • Moreover, each decade of high cholesterol raised the risk of heart disease by 39 percent, suggesting that the cumulative effects of even mild or moderate elevations in cholesterol can pose a significant risk to heart health.

            Under current guidelines, only one in six adults in this group with prolonged duration of  high cholesterol would have been directly recommended for statin therapy at age 40, and one in three at age 50, researchers note. 

Navar-Boggan cautions that, “not every 35-year-old with mild to moderately elevated cholesterol needs to start statin therapy,” but noted that young adults with elevated cholesterol should be aware of their increased future risk of heart disease.

“It’s never too soon for young adults to talk with their doctors about heart health, which should include how to manage cholesterol levels through diet and exercise, and, in certain cases, medication,” Navar-Boggan said. “The plaques in arteries that break off and cause heart attacks later in life take years to develop. What is happening in your blood vessels, in particular your cholesterol levels, during your 30’s and 40’s affects your heart health in your 50’s, 60’s and 70’s.”

Co-authors include E.D. Peterson, M.D., M.P.H.; R.B. D’Agostino, Ph.D.; B. Neely, M.S.; A.D. Sniderman, M.D.; and M.J. Pencina, Ph.D.

This study was supported internally by the Duke Clinical Research Institute in addition to a grant from the Agency for Healthcare Research and Quality. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University.

Additional Resources:

###

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

For Media Inquiries: (214) 706-1173

Carrie Thacker : (214) 706-1665; carrie.thacker@heart.org

Julie Del Barto (broadcast): (214) 706-1330; Julie.DelBarto@heart.org

For Public Inquiries: (800) AHA-USA1 (242-8721)

heart.org and strokeassociation.org

Life is why we fund scientific breakthroughs that save and improve lives. 


Share on:
or:

Health news